Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026
Company Drug

Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in Macao

Fineline Cube Aug 25, 2023

China-based Everest Medicines (HKG: 1952) has announced that its New Drug Application (NDA) for Nefecon,...

Policy / Regulatory

China Releases Third List of Pediatric Drugs to Guide Development and Filings

Fineline Cube Aug 25, 2023

The National Health Commission (NHC), National Healthcare Security Administration, National Medical Products Administration (NMPA), and...

Policy / Regulatory

NMPA Releases 72nd Batch of Reference Drugs for GQCE

Fineline Cube Aug 25, 2023

The National Medical Products Administration (NMPA) has released the 72nd batch of reference drugs for...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Receives European Commission Approval for Maternal Immunization

Fineline Cube Aug 25, 2023

Pfizer (NYSE: PFE) has received registration approval from the European Commission (EC) for its respiratory...

Company Drug

FDA Approves Gilead’s Veklury for COVID-19 Treatment in Patients with Hepatic Impairment

Fineline Cube Aug 25, 2023

The US Food and Drug Administration (FDA) has approved a new indication for Gilead’s (NASDAQ:...

Company Drug

AstraZeneca and MSD’s Lynparza Gets Green Light for Prostate Cancer Treatment in Japan

Fineline Cube Aug 25, 2023

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted AstraZeneca (AZ; NASDAQ: AZN) and...

Company

AstraZeneca Restructures to Capture Opportunities in Guangdong-Hong Kong-Macao Greater Bay Area

Fineline Cube Aug 25, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) is taking strategic steps to capitalize on the...

Company Deals

Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira

Fineline Cube Aug 25, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...

Company Medical Device

Microport EP Medtech’s Cryoablation Catheter and Equipment Approved as Innovative Devices in China

Fineline Cube Aug 25, 2023

Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and...

Company Drug

CSPC Pharmaceutical’s Generic Entresto Approved in China for Heart Failure Treatment

Fineline Cube Aug 25, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Swiss...

Company Drug

Akeso Biopharma’s Ivonescimab Heads for Priority Review for NSCLC Treatment

Fineline Cube Aug 25, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its bispecific antibody (BsAb) ivonescimab (AK112), targeting...

Company

3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing

Fineline Cube Aug 25, 2023

China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...

Company Drug

GSK’s Shingrix Proves 100% Efficacy in Phase IV Trial for Chinese Patients

Fineline Cube Aug 24, 2023

UK-based pharmaceutical giant GSK plc (NYSE: GSK) has released efficacy data for its shingles vaccine,...

Company Deals

ImmuneOnco Biopharmaceuticals Launches IPO to Raise HKD 319 Million on Hong Kong Stock Exchange

Fineline Cube Aug 24, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) is poised to raise HKD 319 million (USD...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Approved by China’s NMPA for NSCLC Treatment

Fineline Cube Aug 24, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that it has received market approval...

Company Drug

Hinova Pharmaceuticals’ HP518 for mCRPC Accepted for Review by China’s NMPA

Fineline Cube Aug 24, 2023

Chengdu-based biotech company Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the National Medical Products...

Company Deals

Labway Clinical Laboratory Partners with 10x Genomics for Precision Medicine Advancements

Fineline Cube Aug 24, 2023

Shanghai Labway Clinical Laboratory Co., Ltd., a leading provider of medical laboratory and pathological diagnostic...

Company Drug

Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE

Fineline Cube Aug 24, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its...

Policy / Regulatory

Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions

Fineline Cube Aug 24, 2023

The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment...

Company

Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials

Fineline Cube Aug 24, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...

Posts pagination

1 … 475 476 477 … 657

Recent updates

  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
  • Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.